PITTSBURGH--(BUSINESS WIRE)--Precision Therapeutics has released the results of a study that determines whether ChemoFx® results change from primary diagnosis to recurrence of disease in gynecological tumors with intervening administration of adjuvant chemotherapy. ChemoFx® is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician.
In Vitro Chemoresponse in Metachronous Pairs of Gynecologic Cancers, recently presented in poster form at the British Gynaecological Cancer Society (BGCS) Annual Meeting held July 5-6, 2012, was conducted by Dr. James Fiorica, who leads the Women’s Cancer Care program at Sarasota Memorial Sarasota Memorial Hospital in Sarasota, Florida.
Two statistical analyses were used to compare chemoresponse between the primary and recurrent setting in 63 cases of metachronous gynecologic tumors where ChemoFx® testing was completed at primary diagnosis and upon recurrence of disease, each 90 days apart. Results showed a trend towards increased chemoresistance at recurrence for the commonly utilized first line agents carboplatin and paclitaxel, but no change for other chemotherapy drugs, including common second line agents doxorubicin, gemcitabine, and topotecan.
These results, which are consistent with clinical observations and established biological concepts, suggest that in vitro assays can be useful tools in research and clinical practice.
"Chemoresponse outcomes compare favorably to clinical observations in treatment trials, suggesting that in vitro assays may be useful tools in research and clinical practice,” says Dr. James Fiorica, primary investigator of the study. “This is especially true in cases where a tumor is rare or extremely aggressive, or where patient survival is poor or unknown.”
The dedicated team at Precision Therapeutics continues its commitment to research and develop improvements in personalized cancer care. More publications and study results are available at www.precisiontherapeutics.com.
About Precision Therapeutics
Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to personalized cancer care. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum. Precision currently receives ChemoFx® specimens from 271 top medical institutions including 20 of the 21 National Comprehensive Cancer Network (NCCN) Member Institutions, and 8 of the US News and World Report Top 10 Hospitals for Cancer Care. To date, approximately 80,000 patient specimens have been submitted for ChemoFx® testing using 105 unique chemotherapy treatments and combinations.
For more information, visit: www.chemofx.com.